• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
In Silico Screening and Immune-Engineering Techniques for “Stealth” Receptor Targets of Immunotherapeutic Antibodies

In Silico Screening and Immune-Engineering Techniques for “Stealth” Receptor Targets of Immunotherapeutic Antibodies

by Annie De Groot | Oct 5, 2018

EpiVax_CPI-Targets_04Oct18_forPrinting
Ancer-designed CT26 RNA Replicon Neo-epitope Vaccine Induces Multi-functional CD4 and CD8 T Cell Responses

Ancer-designed CT26 RNA Replicon Neo-epitope Vaccine Induces Multi-functional CD4 and CD8 T Cell Responses

by Annie De Groot | Oct 5, 2018

EpiVax_ISV2018_CT26_01Oct18_50Wx36H
HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

by Annie De Groot | Oct 5, 2018

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

by Annie De Groot | Aug 15, 2018

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

by Sarah Moniz | Apr 10, 2018

« Older Entries
Next Entries »

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.